Let’s read an article a month – April 2022

The cropped screenshot of the first page of the article. It also includes the URL or link to the article.

Every month I read an open-access article. I share the title and associated link with my followers to encourage clinicians to read more articles, stay up to date, and continue to grow.

The objective of this month’s paper is to  “discover whether there is any difference for Trelegy as compared with multiple inhalers use for adherence, symptoms, medication beliefs, and medication attitudes” (p45).


Chronic obstructive pulmonary disease patients’ experience using Trelegy as compared with other inhalers

By Hyfaa Mashaal, Joshua Fogel, Najia Sayedy, Ruchi Jalota Sahota and Jagadish Akella.

Can J Respir Ther Vol 58. Published online at https://www.cjrt.ca on 25 March 2022

Link to the article: https://www.cjrt.ca/wp-content/uploads/cjrt-2021-041.pdf


A few notes about this article

  • This article provides a quick review of COPD and Trelegy ( Fluticasone furotate, umeclidinium and vilanterol) (pp 44-45).
  • I was surprised to see that there was an increased reported symptoms with Trelegy, and no difference with inhaler adherence when compared to the other medication groups (p 46).  
  • Very important to mention that this is a small sample study. The authors do state that different findings were observed with larger sample size studies;  Check out number 27 and 28 items under the reference list:
    • 27. Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011;14(4):486–96. doi: 10.3111/13696998.2011.594123.
    • 28. Brandstetter S, Finger T, Fischer W, et al. Differences in medication adherence are associated with beliefs about medicines in asthma and COPD. Clin Transl Allergy 2017;7:39. Doi: 10.1186/s13601- 017-0175-6. 

Happy reading and learning,

Farzad Refahi

April 1st, 2022

https://respiratory.blog/lets-read-an-article-a-month-april-2022/

Let’s read an article a month – March 2022

The cropped screenshot of the first page of the article. It also includes the URL or link to the article.

Every month I read an open-access article. I share the title and associated link with my followers to encourage clinicians to read more articles, stay up to date, and continue to grow.

The objective of this month’s paper is to [conduct a comprehensive systematic review, critical appraisal and meta-analysis of all prognostic factories in patients with COVID-19] (p2).


Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis

By Vanesa Bellou, Ioanna Tzoulaki, Maarten van Smeden, Karel G.M. Moons, Evangelos Evangelou and Lazaros Belbasis

European Respiratory Journal 2022 59: 2002964; DOI: 10.1183/13993003.02964-2020 https://erj.ersjournals.com/content/59/2/2002964

Link to the article: https://erj.ersjournals.com/content/erj/59/2/2002964.full.pdf


The reasons I found this article interesting

  • The authors emphasized the importance of “adequate and transparent reporting of methodology and findings in future studies to improve the applicability of the evidence” (p8).   More on that under the ‘Recommendations and policy implications’ on page eight. 
  • This study address many prognostic factors and narrow down to a few such as age, sex and smoking history (p7).
  • The authors further discuss some of the predictors such as dyspnea and hospitality rate, oxygen saturation and mortality, and smoking and clinical deterioration (p7).  
  • Also, some of the medications and their prognostic factors were highlighted.  E.g. ACEi, ARBs, immunosuppressive medications etc. 

Happy reading and learning,

Farzad Refahi

March 2, 2022

Let’s read an article a month – March 2022